New combo therapy aims to boost immunity against early blood cancer
NCT ID NCT01351896
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 24 times
Summary
This study tests whether the drug lenalidomide, combined with a vaccine, can help the immune system fight early-stage chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in people with high-risk genetic features. About 49 participants will receive the treatment to see if it improves antibody responses and controls the disease. The goal is to strengthen the body's natural defenses rather than cure the cancer outright.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
Conditions
Explore the condition pages connected to this study.